FGEN logo

FibroGen, Inc

FGEN

FGEN: FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

more

Show FGEN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of FGEN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by FGEN's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
  • Patent Title: Enhanced erythropoiesis and iron metabolism Jun. 20, 2023
  • Patent Title: Methods for treatment of motor neuron diseases Apr. 12, 2022
  • Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jan. 25, 2022
  • Patent Title: Enhanced erythropoiesis and iron metabolism Feb. 23, 2021
  • Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 19, 2021
  • Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 05, 2021
  • Patent Title: Pharmaceutical formulations of a hif hydroxylase inhibitor Sep. 08, 2020
  • Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 12, 2020
  • Patent Title: Methods for treating idiopathic pulmonary fibrosis Feb. 11, 2020
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 30, 2019
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 06, 2018
  • Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Oct. 09, 2018
  • Patent Title: Methods for treating idiopathic pulmonary fibrosis Aug. 07, 2018
  • Patent Title: Enhanced erythropoiesis and iron metabolism Mar. 20, 2018
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Mar. 20, 2018
  • Patent Title: Compounds and methods for treatment of stroke Oct. 03, 2017
  • Patent Title: Process for making isoquinoline compounds Jul. 18, 2017
  • Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Jul. 04, 2017
  • Patent Title: Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid May. 09, 2017
  • Patent Title: Therapeutic method for pancreatic cancer Apr. 25, 2017
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Apr. 11, 2017
  • Patent Title: Treatment method for lung remodeling diseases Mar. 07, 2017
  • Patent Title: Methods for treating idiopathic pulmonary fibrosis Nov. 01, 2016
  • Patent Title: 4-hydroxy-isoquinoline compounds as hif hydroxylase inhibitors Aug. 09, 2016
  • Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Jul. 12, 2016
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Jun. 21, 2016
  • Patent Title: Process for making isoquinoline compounds May. 17, 2016
  • Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof May. 17, 2016
  • Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Mar. 01, 2016
  • Patent Title: Cyanoisoquinoline compounds and methods of use thereof Nov. 03, 2015
  • Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Oct. 06, 2015
  • Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 25, 2015
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Aug. 25, 2015
  • Patent Title: Therapeutic method Aug. 11, 2015
  • Patent Title: Connective tissue growth factor antibodies May. 19, 2015
  • Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 07, 2015
  • Patent Title: Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity Feb. 10, 2015
  • Patent Title: Thiochromene derivatives as hif hydroxylase inhibitors Jan. 06, 2015
  • Patent Title: Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase Dec. 30, 2014
  • Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Dec. 23, 2014
  • Patent Title: Crystalline forms of a prolyl hydroxylase inhibitor Nov. 11, 2014
  • Patent Title: Treatments for pancreatic cancer metastases Oct. 21, 2014
  • Patent Title: Connective tissue growth factor antisense oligonucleotides Aug. 12, 2014
  • Patent Title: Methods for treatment of muscular dystrophy Jul. 08, 2014
  • Patent Title: Nitrogen-containing heteroaryl compounds and methods of use thereof Jul. 01, 2014
  • Patent Title: Cyanoisoquinoline compounds and methods of use thereof Jun. 24, 2014
  • Patent Title: Treatments for cancer May. 20, 2014
  • Patent Title: Thienopyridine compounds, and methods of use thereof Apr. 22, 2014
  • Patent Title: Enhanced erythropoiesis and iron metabolism Jan. 14, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of FGEN in WallStreetBets Daily Discussion

FGEN News

Recent insights relating to FGEN

CNBC Recommendations

Recent picks made for FGEN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in FGEN

Corporate Flights

Flights by private jets registered to FGEN